Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Inflammatory Myopathies Difficult to Diagnose, Treat

Jonathan Jones, MD, and Robert Wortmann, MD  |  Issue: December 2013  |  

Dr. Jones is assistant professor of medicine and Dr. Wortmann is professor emeritus of medicine at the Geisel School of Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, N.H. Disclosure: Dr. Wortmann is on an advisory board for Questcor Pharmaceuticals.

References

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.
  2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-407.
  3. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol. 2006;97(8A):52C-60C.
  4. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology (Oxford). 2002;41:22-26.
  5. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757-2766.
  6. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14:275-285.
  7. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324.
  8. Bunch TW. Prednisone and azathioprine for polymyositis: Long-term followup. Arthritis Rheum. 1981;24:45-48.
  9. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380-1384.
  10. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
  11. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392-399.
  12. Coyle K, Pokrovnichka A, French K, et al. A randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2008;58(Suppl):Abstract: 2058.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…